Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of inactivated SARS-CoV-2 vaccine (Vero cell) in healthy adults
ChiCTR2000039000Phase 3Recruiting
- Sponsor
- China National Biotec Group
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of inactivated sars-cov-2 vaccine (vero cell) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by China National Biotec Group. Primary endpoint: 4-fold increase rate and antibody level of anti-SARS-CoV-2 neutralizing antibody. Started Sep 2020; status: recruiting.
02
Drugs
inactivated sars-cov-2 vaccine (vero cell)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000039000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039000.